Compass Pathways Plc - Company Profile
Powered by 
All the data and insights you need on Compass Pathways Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Compass Pathways Plc Strategy Report
- Understand Compass Pathways Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Compass Pathways Plc (Compass Pathways) is a biotechnology company that carries out the development of mental health treatments. The company provides the development of COMP360 psilocybin treatment, a novel approach to mental health care that combines a proprietary psilocybin formulation with psychological support. Compass Pathways products are designed for use in the healthcare industry for the treatment of mental health conditions. It collaborates with research institutions and partners. Compass Pathways is headquartered in Altrincham, Cheshire, the UK.
Headquarters
United Kingdom
Address
3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA142DT
Website
compasspathways.com
Telephone
44 1646 9053974
No of Employees
186
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CMPS (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-29.5%
(2022 vs 2021)
Market Cap*
$583.7M
* As of and is in US$
Compass Pathways Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Phase IIb Clinical Candidate: |
| COMP360: Treatment-Resistant Depression, Major Depressive Disorder, Post-Traumatic Stress Disorder, Anorexia |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company entered into a partnership with Journey Clinical to address the needs of Americans suffering from mental illness. |
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with Greenbrook TMS to investigate the delivery models for COMP360 psilocybin treatment. |
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with Hackensack Meridian Health to develop a model for investigational COMP360 psilocybin treatment. |
Competitor Comparison
| Key Parameters | Compass Pathways Plc | Axsome Therapeutics Inc | Janssen Research & Development LLC | Minerva Neurosciences Inc | Relmada Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | United States of America | United States of America | United States of America |
| City | Altrincham | New York | Raritan | Waltham | Coral Gables |
| State/Province | Cheshire | New York | New Jersey | Massachusetts | Florida |
| No. of Employees | 186 | 545 | - | 9 | 20 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Norton | Chairman | Executive Board | 2024 | 72 |
| Kabir Nath | Chief Executive Officer; Director | Executive Board | 2022 | 59 |
| Teri Loxam | Chief Financial Officer | Senior Management | 2024 | 52 |
| Greg Ryslik | Chief Technology Officer | Senior Management | - | - |
| Matthew Owens | General Counsel; Chief Legal Officer | Senior Management | 2022 | 46 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer